文献

J-GLOBAL ID：201902247483652544   整理番号：19A2479575

進行/再発大腸癌に対するサードライン化学療法としての隔週TAS-102とベバシズマブの試験プロトコール:第II相多施設臨床試験(TAS-CC4試験)

A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study)

著者 (12件)： Yoshida Yoichiro (Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine) ,  Yamada Takeshi (Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School) ,  Matsuoka Hiroshi (Department of Surgery, Fujita Health University School of Medicine) ,  Sonoda Hiromichi (Department of Surgery, Shiga University of Medical Science) ,  Fukazawa Atsuko (Department of Gastroenterological Surgery, Iwata City Hospital) ,  Yoshida Hiroshi (Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School) ,  Ishida Hideyuki (Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University) ,  Hirata Keiji (Department of Surgery 1, School of Medicine, University of Occupational and Environmental Health) ,  Hasegawa Suguru (Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine) ,  Sakamoto Kazuhiro (Department of Coloproctological Surgery, Juntendo University Faculty of Medicine) ,  Otsuka Toshiaki (Department of Hygiene and Public Health, Graduate School of Medicine, Nippon Medical School) ,  Koda Keiji (Department of Surgery, Teikyo University Chiba Medical Center)
資料名： Journal of the Anus, Rectum and Colon (Web)  (Journal of the Anus, Rectum and Colon (Web))
巻： 3  号： 3  ページ： 136-141(J-STAGE)  発行年： 2019年 
JST資料番号： U1442A  ISSN： 2432-3853  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： 日本 (JPN)  言語： 英語 (EN)

抄録/ポイント： 背景:TAS-102治療は転移大腸癌(mCRC)患者の無進行...

シソーラス用語： 進行癌 ,...
準シソーラス用語： 進行/再発大腸癌 ,...

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A2479575&from=J-GLOBAL&jstjournalNo=U1442A") }}

著者キーワード (4件)： 大腸癌 ,  TAS-102 ,  隔週投与 ,  好中球減少

分類 (3件)： 抗腫よう薬の臨床への応用  (GW16020L) ,  腫ようの薬物療法  (GE03032C) ,  消化器の腫よう  (GH04000D)

物質索引 (1件)： TAS-102

引用文献 (15件)：

• 1. Emura T, Murakami Y, Nakagawa F, et al. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. International journal of molecular medicine. 2004 Apr; 13 (4): 545-9.
• 2. Chen J, Han M, Saif MW. TAS-102 an Emerging Oral Fluoropyrimidine. Anticancer research. 2016 Jan; 36 (1): 21-6.
• 3. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. The New England journal of medicine. 2015 May; 372 (20): 1909-19.
• 4. Kuboki Y, Nishina T, Shinozaki E, et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. The Lancet Oncology. 2017 Sep; 18 (9): 1172-81.
• 5. Sueda T, Sakai D, Kudo T, et al. Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies. Anticancer research. 2016 Aug; 36 (8): 4299-306.

タイトルに関連する用語 (8件)： 再発大腸癌 ,  サードライン化学療法 ,  TAS-102 ,  ベバシズマブ ,  試験 ,  プロトコール ,  第II相 ,  多施設臨床試験